SHR-1916 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy. (PubMed, Drug Des Devel Ther) - "SHR-1916 exhibited excellent cellular selectivity, anti-tumor efficacies, and improved pharmacokinetics. It has the potential to serve as a novel immunotherapeutic agent designed to enhance IL-2's immune-stimulating activities and promote its tolerability while reducing the immunoregulatory function of Treg cells."

Journal • PK/PD data • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor • CD8 • IFNG • IL2

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=50 ➔ 11 | Recruiting ➔ Terminated; R&d strategy adjustment

Enrollment change • Metastases • Trial termination • Oncology • Solid Tumor

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor • CD8

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=50; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Oncology • Solid Tumor • CD8